Sobi is a drugmaker focused on hemophilia, inflammation, and genetic and metabolic diseases. It is now pursuing its drug Orfadin, used to treat the metabolic disorder Tyrosemia Type 1, as a potential treatment for the metabolic condition Alkaptonuria. It is also pursuing Kineret, a drug for the rare inflammatory condition NOMID, as a potential therapy for Still’s Disease. We spoke to Rami Levin, President of North America for Sobi, and Len Walt, VP & Head of Medical Affairs of North America for Sobi, about the company’s evolution, its growing pipeline, and its effort to expand indications for its rare disease drugs.
RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here. 

X